Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 22-27

Karger

Access to resources Recommend Favorite

The Role of Consolidative Radiotherapy after a Complete Response to Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma in the Rituximab Era: Results from a Systematic Review with a Meta-Analysis

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 111-118

Karger

Access to resources Recommend Favorite

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 219-226

John Wiley & Sons Inc

Access to resources Recommend Favorite